Human papillomavirus peptide-HLA class I complex (HPV pHLA)

The Human papillomavirus (HPV) peptide-HLA class I complex is a specialized molecular target consisting of viral protein fragments (epitopes) bound to the major histocompatibility complex (MHC) on the surface of infected or cancerous cells [1.3.1, 1.3.2]. These peptides are primarily derived from the high-risk HPV oncoproteins E6 and E7, which are essential for maintaining the malignant phenotype by degrading p53 and pRb, respectively [1.3.2, 1.4.1]. Because these oncoproteins are intracellular, they are not accessible to conventional antibodies; however, their presentation as peptide-HLA complexes allows the immune system to identify and eliminate the affected cells via CD8+ cytotoxic T lymphocytes [1.3.2, 1.5.1]. This target is the focus of several advanced immunotherapeutic modalities, including T-cell receptor (TCR) engineered T-cells, therapeutic vaccines (e.g., SQZ-PBMC-HPV, DPX-E7), and TCR-mimic (TCRm) antibodies that recognize the specific peptide-HLA configuration [1.1.1, 1.3.2, 1.5.1]. A major challenge in targeting this complex is the requirement for HLA matching, as different HLA alleles present different sets of peptides, and the potential for tumor immune evasion through the downregulation of the antigen processing machinery [1.1.1, 1.3.1, 1.5.2]. Therapeutic strategies aim to overcome these hurdles by identifying immunodominant epitopes and using combination therapies with immune checkpoint inhibitors to enhance the durability of the T-cell response [1.1.1, 1.5.1].

Other names

HPV-derived antigenic peptides presented on HLA class IHPV peptide-MHC class I complexHPV E6/E7 peptide-HLA complexHPV-specific HLA-restricted epitopesHPV pHLA complex

Induction or redirection of antigen-specific cytotoxic T-cell responses against cells presenting viral epitopes [1.3.2, 1.5.1].